Nurix Therapeutics, Inc. Common stock
Symbol: NRIX (NASDAQ)
9.19
▼ (-2.23%) -0.210
Company Description:
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
Key Stats
- Today's Open: $9.44
- Today's High: $9.595
- Today's Low: $9.21
- Today's Volume: 149.87K
- Yesterday Close: $9.4
- Yesterday High: $9.75
- Yesterday Low: $9.26
- Yesterday Volume: 3.66M
- Last Min Volume: 153
- Last Min High: $9.214
- Last Min Low: $9.21
- Last Min VWAP: $9.21016
Company Profile
- Name: Nurix Therapeutics, Inc. Common stock
- Website: http://www.nurixtx.com
- Listed Date: 2020-07-24
- Location: SAN FRANCISCO, CA
- Market Status: Active
- CIK Number: 0001549595
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $718.62M
- Round Lot: 100
- Outstanding Shares: 76.45M
- Asset Type: CS
RECENT FILINGS FOR NRIX
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-17 | 4 | View |
| 2025-09-03 | 8-K | View |
| 2025-08-22 | 8-K | View |
| 2025-08-01 | 4 | View |
| 2025-08-01 | 144 | View |
| 2025-07-30 | 4 | View |
| 2025-07-30 | 4 | View |
| 2025-07-30 | 4 | View |
| 2025-07-09 | 10-Q | View |
| 2025-07-09 | 8-K | View |
| 2025-06-12 | 8-K | View |
| 2025-05-19 | 4 | View |
| 2025-05-19 | 4 | View |
| 2025-05-19 | 4 | View |
| 2025-05-19 | 4 | View |
| 2025-05-19 | 4 | View |
| 2025-05-19 | 4 | View |
| 2025-05-19 | 4 | View |
| 2025-05-19 | 4 | View |
| 2025-05-19 | 8-K | View |
Latest News on NRIX